Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14141475 | 0.86 | AHR (0.34) | AHR | |
| SCHEMBL13357807 | 0.80 | AHR (0.37) | AHRMEN1MAPTKMT2AABCG2 | |
| SCHEMBL7026027 | 0.79 | AHR (0.35) | AHRMEN1MAPTKMT2ATP53 | |
| SCHEMBL13839616 | 0.77 | MEN1 (0.47) | AHRMEN1MAPTKMT2ATP53 | |
| SCHEMBL17280459 | 0.76 | AHR (0.37) | AHRMEN1MAPTKMT2ATP53 | |
| SCHEMBL13839470 | 0.76 | AHR (0.37) | AHRMEN1MAPTKMT2ACYP3A4 | |
| SCHEMBL13839496 | 0.76 | L3MBTL1 (0.40) | AHRMEN1MAPTKMT2AABCG2 | |
| SCHEMBL12850174 | 0.75 | AHR (0.34) | AHR | |
| SCHEMBL19754861 | 0.75 | AHR (0.36) | AHRMEN1MAPTKMT2ACYP3A4 | |
| SCHEMBL4625191 | 0.74 | ABCG2 (0.39) | AHRMEN1MAPTKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615645-B2 | Method for the continuous production of aldehydes | BASF AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615645-B2 | Method for the continuous production of aldehydes | BASF AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-20070083066-A1 | Method for the production of 1,7-octadiene and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-12 | — | — | US | disclosed |
| US-20070083066-A1 | Method for the production of 1,7-octadiene and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-12 | — | — | US | disclosed |
| US-20070004939-A1 | Method for the continuous production of aldehydes | VOLLAND MARTIN | 2007-01-04 | — | — | US | disclosed |
| US-20070004939-A1 | Method for the continuous production of aldehydes | VOLLAND MARTIN | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004939-A1 | Method for the continuous production of aldehydes | HRH4, HRH2, HRH3 | AHR 605/4885MEN1 911/4885MAPT 4835/4885 |
| US-20070083066-A1 | Method for the production of 1,7-octadiene and use thereof | CYP51A1, MSMO1, HSD17B7 | AHR 573/4885MEN1 290/4885MAPT 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.